Placebo for schizophrenia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Aug 2025: Trial started, NCT07145918
  2. 28 Aug 2025: Trial registered, NCT07145918

The trials

NCT07145918: A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

State
Under way
Phase
Phase 2
People
268 planned
Started
4 Aug 2025
Primary completion
Feb 2028
Arms
Placebo-Part A, Placebo-Part B
Results
None posted
  1. 4 Aug 2025: Trial started
  2. 28 Aug 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.